Kennedy Capital Management LLC Acquires 20,009 Shares of LivaNova PLC $LIVN

Kennedy Capital Management LLC lifted its holdings in LivaNova PLC (NASDAQ:LIVN) by 8.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 245,732 shares of the company’s stock after acquiring an additional 20,009 shares during the period. Kennedy Capital Management LLC owned approximately 0.45% of LivaNova worth $15,120,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Hantz Financial Services Inc. raised its position in shares of LivaNova by 159.9% in the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after acquiring an additional 267 shares in the last quarter. State of Wyoming bought a new position in shares of LivaNova in the 2nd quarter worth about $31,000. EverSource Wealth Advisors LLC raised its position in shares of LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after acquiring an additional 639 shares in the last quarter. Quarry LP bought a new position in shares of LivaNova in the 3rd quarter worth about $36,000. Finally, Covestor Ltd raised its position in shares of LivaNova by 108.6% in the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock worth $46,000 after acquiring an additional 392 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

LivaNova Price Performance

LivaNova stock opened at $79.39 on Monday. LivaNova PLC has a 52 week low of $41.01 and a 52 week high of $80.74. The company’s 50 day moving average price is $69.08 and its two-hundred day moving average price is $65.81. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. The stock has a market cap of $4.36 billion, a P/E ratio of 40.71 and a beta of 0.88.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.13. The company had revenue of $362.26 million for the quarter, compared to analysts’ expectations of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. LivaNova’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, equities analysts predict that LivaNova PLC will post 3.73 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on LIVN. Needham & Company LLC lifted their price objective on LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Stifel Nicolaus set a $80.00 target price on LivaNova in a research report on Wednesday, February 25th. Robert W. Baird decreased their target price on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Mizuho boosted their target price on LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $79.38.

Insider Activity at LivaNova

In related news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the sale, the director owned 7,228 shares of the company’s stock, valued at approximately $547,521. The trade was a 19.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.35% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.